Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

The post Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk appeared first on Investor’s Business Daily.